DXC Technology and Lenovo Partner with Dr. Peter Scott-Morgan on Innovative Technology Accessibility Solutions to Create Better Futures for People with Disabilities
DXC Technology (NYSE: DXC) and Lenovo today announced a collaboration with visionary robotics scientist Dr. Peter Scott-Morgan and his philanthropic foundation to develop ambitious assistive technology solutions by integrating the latest hardware, software, and artificial intelligence (AI) technologies to empower people with disabilities, illnesses, and other challenging conditions.
Scott-Morgan, known as the “world’s first human cyborg", is pushing technology to extend and enrich lives. He was diagnosed with motor neuron disease (MND) – also known as amyotrophic lateral sclerosis (ALS) – in 2017. When the first symptoms emerged, Scott-Morgan began exploring ways to upend the typical disease progression through his belief in the limitless potential of technology. Scott-Morgan’s vision is to: “Make the vulnerable safe, the powerless strong, the unfulfilled thrive.”
“The bedrock of our collaboration is a belief in the untapped potential of technology to unleash your dreams - whatever you are, whatever your background, whatever your circumstances, whatever your ambitions,” Scott-Morgan said. Initially told by doctors he had only two years to live, Scott-Morgan has a mantra: “Add hopewith AI and Robotics!”
DXC and Lenovo – alongside a team of volunteers and leading technologists – will provide hardware, software support, integration, and artificial intelligence expertise. Key initiatives include:
- Developing autonomous, self-driving wheelchairs to navigate homes and beyond;
- Preserving personality with an avatar that renders quickly in photo-realistic detail;
- Leveraging augmented reality (AR) as a user interface controlled with only eye movements;
- Accelerating the generation and customization of emotionally expressive digital voices; and
- Embedding smart technology throughout a family home to enhance the life of all its occupants.
In addition to developing custom solutions, Lenovo has donated computing equipment for Scott-Morgan’s home-office. Calvin Crosslin, Lenovo’s Chief Diversity Officer and President of the Lenovo Foundation said: “We have a responsibility to make powerful technology as accessible as possible and create new opportunities. This is precisely why we rally behind the idea of smarter technology for all, and I am grateful to Dr. Scott-Morgan for inviting us to collaborate and share some small part of his extraordinary vision.”
DXC will act as technology integrator. Deploying capabilities from the Enterprise Technology Stack, DXC will bring technology know-how and experience to ensure seamless and secure integration across infrastructure, applications, analytics, and engineering solutions.
“Peter is an astonishing inspiration,” said Steve Turpie, President, EMEA at DXC. “The DXC team will offer consulting and support to define requirements, the target architecture, and the technology roadmap. Specifically, they will enable the functions for eye tracking, virtual keyboards, speech, and avatar performance. Peter, with the Foundation, has a tireless passion to challenge our thinking on how technology can be used to enhance people’s lives and society.”
Learn more about Dr. Peter Scott-Morgan, including his background, ongoing research, and opportunities to get involved through The Scott-Morgan Foundation.
“I applied a lifetime of research to rewrite my own future - an extraordinarily lucky break! But far more important, we’ve now the chance to rewrite the future for millions - eventually billions - by applying the lessons learned to make the vulnerable safe, the powerless strong, the unfulfilled thrive. I wanted a way to break free of my suddenly inadequate body, to overcome a devastating diagnosis and reimagine what ‘terminal disease’ could mean. But we can help everyone who feels disadvantaged. They can rise like a phoenix! With extraordinary support from my husband Francis, countless kind and brilliant collaborators, and technology leaders like DXC and Lenovo, I find the once-dark future incredibly bright.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
About Lenovo Tech World 2021 and Dr Peter Scott-Morgan
Scott-Morgan joined Lenovo at its Tech World 2021 event on September 8 to speak with Thorsten Stremlau, Lenovo’s director of strategic enterprise consulting, about their shared goals of delivering smarter technology for all.
“I am deeply humbled to work with Peter, an absolutely brilliant scientist and inspiring human,” said Stremlau, who is leading Lenovo’s efforts. “We focus a lot on increasing accessibility and diversity at Lenovo, and this is a singular opportunity to ensure our innovation makes a real difference – for both Peter and, I hope, many others.”
About other partners supporting The Scott-Morgan Foundation
Other key collaborators already working with Scott-Morgan on this initiative include Matthew Aylett of CereProc, Amanda Darby of Optimize3D at Pinewood Studios, and Ari Shapiro of Embody Digital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Antoine Roussel, Communications EMEA: firstname.lastname@example.org
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pencil Lab Inks Debut in ADIHEX 202125.9.2021 12:04:00 CEST | Press release
The 18th edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) on September 27 - October 3 marks an opportune platform for Pencil Lab Design Studio’s first major participation in the massive event, the largest of its kind in the Middle East and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210925005016/en/ Pencil Lab Inks Debut in ADIHEX 2021 (Photo: AETOSWire) Featuring more than 800 brands and companies, the event is held under the theme of ‘Sustainability and Heritage… A Reborn Aspiration’, highlighting heritage, culture and authentic sports and their strong relation with Arab history. As part of its inaugural participation in a major exhibition as a company, Pencil Lab, a UAE initiative, will showcase their artworks with three large oil paintings by Pencil Lab’s citizen artist, to highlight the strong connection of arts, like painting and photography, to Arab history and civilization.
DXC Technology Completes Refinancing Actions24.9.2021 22:30:00 CEST | Press release
DXC Technology Company (NYSE: DXC) (“DXC”) today announced the completion of its refinancing. DXC previously completed the offering of €1.35 billion Senior Notes priced on September 2, 2021 and $1.35 billion Senior Notes priced on September 7, 2021. DXC completed redemption of $2.5 billion principal of (i) EUR term loan in the amount of €400 million due FY23 and FY24, (ii) $500 million 4.25% Senior notes due FY25, (iii) £250 million 2.75% Senior notes due FY25, (iv) $467 million 4.125% Senior notes due FY26, (v) $500 million 4.75% Senior notes due FY28, and (vi) $234 million Senior notes due FY30. The applicable make whole premium for these redemptions was $300 million and accrued and unpaid interest was $40 million. Ken Sharp, Chief Financial Officer, DXC commented: “Our opportunistic debt refinancing of $2.5 billion of our high coupon debt further solidifies our financial foundation by extending our debt maturities, lowering our maturity towers and reducing our ongoing interest expen
Schlumberger Announces Third-Quarter 2021 Results Conference Call24.9.2021 16:00:00 CEST | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on October 22, 2021 to discuss the results for the third quarter ending September 30, 2021. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 22, 2021, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402
Tradeweb Successfully Completes its First Southbound Bond Connect Transactions24.9.2021 14:07:00 CEST | Press release
Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has completed its first Southbound Bond Connect transactions via the trading link between Tradeweb and China Foreign Exchange Trade System (CFETS). “Southbound Bond Connect is the latest evolutionary step for China’s financial market, providing domestic investors with more flexibility and choice when trading offshore bonds,” said Lee Olesky, CEO of Tradeweb Markets. “Together with CFETS, our goal is to better meet onshore investors’ demand for streamlined access to global investment. We will continue to focus on further enhancing the trading link by deploying new innovative trading functionality, just as we did with the Northbound leg of Bond Connect.” Southbound Bond Connect facilitates fixed income portfolio diversification for institutional investors in China. Tradeweb collaborates closely with CFETS to create a uniform trading ex
H.I.G. Capital Acquires Aspire Pharma24.9.2021 14:05:00 CEST | Press release
H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (“Aspire” or the “Company”), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye. The financial terms of the transaction have not been disclosed. Aspire licenses and develops niche generic and specialty pharmaceutical products that offer innovative formulations, value for money for payors, and reliable supply arrangements in markets that are often underserved. The business holds leadership positions in urology, ophthalmology, CNS and dermatology, with a highly diversified portfolio of more than 250 products across multiple categories, including branded specialty products and unbranded niche generics. H.I.G., together with the management team, aims to continue Aspire’s strong track record of organic growth and
Swappable Announces Partnership with Esports T1's Dota 2 Team24.9.2021 13:34:00 CEST | Press release
Swappable, an NFT (Non-Fungible Token) interface for high-profile and exclusive digital collectibles, has announced its partnership with T1's Dota 2 team, the popular esports team for the upcoming International 10 - Dota 2 World Championship in Bucharest, Romania. T1 is not just an esports team but a pop culture phenomenon with millions of fans worldwide. The team embodies a blend of lifestyle, creativity and attitude, fresh from the source of Seoul & LA. As part of the collaboration, T1 will auction their first-ever NFTs (digital collectibles) on Swappable for T1’s Genesis Collection. With the first auction starting Friday September 24th, T1 will release a series of NFTs each possessing utility features such as special access to T1's Dota 2 team players and more. Visit Swappable for more information. “We are excited to partner with a leading organization in the esports industry. It is also a chance for T1 fans to pick the very first digital collectibles ever created by this legendary
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-1924.9.2021 13:00:00 CEST | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. It is being assessed in the ACTIV-2 trial funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 is advancing to the Phase 3 trial based on meeting pre-defined graduation crite